SCHEMBL23218400

SCHEMBL23218400

CCOC(=O)Cc1ccccc1Cc1coc2ccc(-c3cccc(CNC(=O)OC(C)(C)C)c3)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.42
HDAC1 Q13547 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
BRD4 O60885 1/20 0.37
CREBBP Q92793 1/20 0.37
PSMB5 P28074 1/20 0.37
CASP1 P29466 1/20 0.37
GLS O94925 3/20 0.36
PPID Q08752 2/20 0.35
CTSB P07858 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
SCN9A Q15858 1/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
THRB P10828 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852595 1.00 TP53 (0.42) TP53HDAC1L3MBTL1BRD4CREBBP
SCHEMBL29852896 0.83 CFD (0.43) TP53PSMB5CASP1POLBGAA
SCHEMBL23218288 0.83 CFD (0.43) TP53PSMB5CASP1POLBGAA
SCHEMBL29852677 0.83 TP53 (0.36) TP53HDAC1L3MBTL1BRD4CREBBP
SCHEMBL23218237 0.83 TP53 (0.36) TP53HDAC1L3MBTL1BRD4CREBBP
SCHEMBL29852557 0.83 GRM2 (0.36) TP53HDAC1BRD4CREBBPCASP1
SCHEMBL23218162 0.83 GRM2 (0.36) TP53HDAC1BRD4CREBBPCASP1
SCHEMBL29591274 0.83 BRD4 (0.44) TP53HDAC1BRD4CREBBPGLS
SCHEMBL23219014 0.83 BRD4 (0.44) TP53HDAC1BRD4CREBBPGLS
SCHEMBL29853011 0.83 BRD4 (0.44) TP53HDAC1BRD4CREBBPGLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TP53 3891/4885HDAC1 1325/4885L3MBTL1 4262/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TP53 3580/4885HDAC1 2275/4885L3MBTL1 4650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.